Two years after receiving Medtronic plc's Heartware ventricular assist device (HVAD) via a less-invasive implant procedure, 95% of patients were free from disabling stroke, according to the Dublin-based company. Adverse events, if they did occur, were mostly seen within the first 30 days following implant, with total strokes occurring at only 0.05 events per patient year (EPPY) in years one to two post-implant. Results of the LATERAL clinical trial were presented at the American Society for Artificial Internal Organs 65th annual conference in San Francisco. Read More
